Hepatitis C

News Hepatitis C

• Frost & Sullivan: Combination drugs are the future of the European Hepatitis B and C therapeutics markets

  The limited efficacy and negative side-effects associated with current therapeutics for Hepatitis B and C are highlighting the urgent need for new, improved alternatives. Combination therapies offering better clinical outcomes are coming to the fore and look set to transform the European market for more

• Study finds interferon, one of the body's proteins, induces persistent viral infection

  Scientists at The Scripps Research Institute (TSRI) have made a counterintuitive finding that may lead to new ways to clear persistent infection that is the hallmark of such diseases as AIDS, hepatitis B and hepatitis C. The study, reported in the journal Science, focused on the activity of the body more

• Expanding high risk population drives European hepatitis B and C diagnostics market, finds Frost & Sullivan

  In recent years, the prevalence of hepatitis C has increased among high risk sub-group populations, including immigrants from areas where the disease is endemic, injecting drug users (IDUs) and patients co-infected with HIV. “Overall, the incidence of hepatitis C among IDUs in Europe is estimated to more

White papers Hepatitis C

• Identification of a New Arenavirus Using High-Throughput Sequencing
  

  Culture, PCR, serologic, and oligonucleotide microarray analyses for a wide range of infectious agents were negative in samples from three individuals who had received organ transplants from a single donor and died of a febrile illness 4-6 weeks after transplantation. Palacios et al. used high-troughput sequencing with the Genome Sequencer FLX system to identify microbial sequences from RNA samples taken from the liver and kidney transplants in two recipients. They found 14 sequences representing an Old World arenavirus related to lymphocytic choriomeningitis viruses. more

Publications Hepatitis C

• Understanding the Biological Context of NS5A–Host Interactions in HCV Infection: A Network-Based Approach

  Hepatitis C virus (HCV) is a major cause of chronic liver disease. HCV NS5A protein plays an important role in HCV infection through its interactions with other HCV proteins and host factors. In an attempt to further our understanding of the biological context of protein interactions between NS5A an more

• Correction

  Correction Nature 497, 7449 (2013). http://www.nature.com/doifinder/10.1038/497301a The News story ‘Targeted drugs to tackle hepatitis C’ (Nature497, 18–19; 2013) wrongly implied that the US Preventive Services Task Force considers financial co more

• Structural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization Escape

  by Thomas Krey, Annalisa Meola, Zhen-yong Keck, Laurence Damier-Piolle, Steven K. H. Foung, Felix A. Rey The high mutation rate of hepatitis C virus allows it to rapidly evade the humoral immune response. However, certain epitopes in the envelope glycoproteins cannot vary without compromising vir more

Market studies Hepatitis C

• Caleco Pharma Corp. - Strategic SWOT Analysis Review

  Caleco Pharma Corp. (Caleco) is a public company engaged in the development of products to treat moderate to severe liver maladies. The company is developing its proprietary technology for the treatment of moderate to severe liver maladies which include conditions like elevated liver enzymes and the more

• Hepatitis C – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Hepatitis C - Pipeline Review, H1 2012', provides an overview of the Hepatitis C therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis C, complete with latest updates, and special features on late-stage and discon more

• Medivir AB (MVIR B) - Financial and Strategic SWOT Analysis Review

  Medivir AB (Medivir) is a pharmaceuticals company. It undertakes the research and development of drugs for high-value treatments of infectious diseases. The company operates through two business segments, namely, Pharmaceuticals segment and Parallel Import segment. The Pharmaceuticals segment compri more

Websites Hepatitis C